Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

6990 · HKEX

Public Market Listing

6990HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(7 total)
7Total Assets
0Approved
2Phase 3 / Filed
5Phase 1–2 / Early
11Diseases
Quick filter:
Showing 7 of 7 assets
Target & Modality
Phase 3
TROP2Antibody–drug conjugate
Non-Small Cell Lung CancerBreast CancerOvarian CancerCervical CancerBladder CancerEndometrial Cancer
HR+/HER2- Metastatic Breast Cancer
Phase 3
PD-L1Monoclonal antibody
Non-Small Cell Lung CancerBreast CancerNasopharyngeal Carcinoma
HR+/HER2- Metastatic Breast Cancer
Phase 2/3
TSLPMonoclonal antibody
Chronic Obstructive Pulmonary DiseaseAsthma
Phase 2
EGFR x c-METAntibody–drug conjugate
Non-Small Cell Lung Cancer
Phase 1/2
PD-1 + VEGFMultispecific antibody
Solid Tumors
Phase 1/2
RETSmall molecule
Non-Small Cell Lung Cancer
Phase 1
TSLPMultispecific antibody
Atopic DermatitisAsthma

Upcoming events

(56 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (5)
November 2026 (1)
Sacituzumab TirumotecanPhase 3Non-Small Cell Lung Cancer
Est. primary completion 2026-11 · NCT06448312 · CT.gov ↗
What to watch
December 2026 (4)
Sacituzumab TirumotecanPhase 3Non-Small Cell Lung Cancer
Est. primary completion 2026-12 · NCT06711900 · CT.gov ↗
What to watch
Sacituzumab TirumotecanPhase 2Selected Subjects With Advanced Solid Tumors
Est. primary completion 2026-12-30 · NCT05631262 · CT.gov ↗
What to watch
LunbotinibPhase 1/2Advanced Solid Tumor
Est. primary completion 2026-12-31 · NCT05265091 · CT.gov ↗
What to watch
Sacituzumab TirumotecanPhase 3Metastatic Breast Cancer
Est. primary completion 2026-12-31 · NCT06081959 · CT.gov ↗
What to watch
2027 (14)
March 2027 (1)
LunbotinibPhase 1/2NSCLC
Est. primary completion 2027-03 · NCT05443126 · CT.gov ↗
What to watch
April 2027 (1)
Sacituzumab TirumotecanPhase 3Triple Negative Breast Cancer
Est. primary completion 2027-04 · NCT06279364 · CT.gov ↗
What to watch
May 2027 (2)
Sacituzumab TirumotecanPhase 3Non-Small Cell Lung Cancer
Est. primary completion 2027-05 · NCT06670196 · CT.gov ↗
What to watch
Sacituzumab TirumotecanPhase 3Non-small Cell Lung Cancer (NSCLC)
Est. primary completion 2027-05-10 · NCT06074588 · CT.gov ↗
What to watch
June 2027 (2)
Sacituzumab TirumotecanPhase 1/2Esophageal Squamous Cell Carcinoma
Est. primary completion 2027-06-11 · NCT05319730 · CT.gov ↗
What to watch
SKB571Phase 2Non-small Lung Cancer
Est. primary completion 2027-06-30 · NCT07308106 · CT.gov ↗
What to watch
July 2027 (2)
Sacituzumab TirumotecanPhase 3Metastatic Breast Cancer
Est. primary completion 2027-07 · NCT07071337 · CT.gov ↗
What to watch
Sacituzumab TirumotecanPhase 3Breast Neoplasms
Est. primary completion 2027-07-11 · NCT06312176 · CT.gov ↗
What to watch
August 2027 (2)
Sacituzumab TirumotecanPhase 2Non-Small Cell Lung Cancer
Est. primary completion 2027-08-31 · NCT07329322 · CT.gov ↗
What to watch
SKB571Phase 2Gastrointestinal Tumors
Est. primary completion 2027-08-31 · NCT07564466 · CT.gov ↗
What to watch
November 2027 (1)
Sacituzumab TirumotecanPhase 2Solid Tumor
Est. primary completion 2027-11-30 · NCT05642780 · CT.gov ↗
What to watch
December 2027 (3)
TagitanlimabPhase 3Nasopharyngeal Carcinoma, Recurrent or Metastatic
Est. primary completion 2027-12 · NCT05294172 · CT.gov ↗
What to watch
WIN378Phase 2COPD (Chronic Obstructive Pulmonary Disease)
Est. primary completion 2027-12-17 · NCT07646587 · CT.gov ↗
What to watch
Sacituzumab TirumotecanPhase 2Non-Squamous Non-Small Cell Lung Cancer
Est. primary completion 2027-12-30 · NCT07854509 · CT.gov ↗
What to watch
2028 (15)
January 2028 (4)
Sacituzumab TirumotecanPhase 2Ovarian Epithelial Cancer
Est. primary completion 2028-01 · NCT07341100 · CT.gov ↗
What to watch
Sacituzumab TirumotecanPhase 3Endometrial Cancer
Est. primary completion 2028-01-10 · NCT06132958 · CT.gov ↗
What to watch
SKB571Phase 2Lung Cancer (Non-Small Cell)
Est. primary completion 2028-01-19 · NCT07230405 · CT.gov ↗
What to watch
Sacituzumab TirumotecanPhase 3Non-small Cell Lung Cancer (NSCLC)
Est. primary completion 2028-01-25 · NCT06170788 · CT.gov ↗
What to watch
February 2028 (1)
SKB571Phase 2Pancreatic Cancer
Est. primary completion 2028-02-28 · NCT07814066 · CT.gov ↗
What to watch
March 2028 (1)
Sacituzumab TirumotecanPhase 1/2Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Est. primary completion 2028-03-31 · NCT06483334 · CT.gov ↗
What to watch
April 2028 (1)
Sacituzumab TirumotecanPhase 2Thymic Carcinoma
Est. primary completion 2028-04 · NCT07324629 · CT.gov ↗
What to watch
May 2028 (1)
Sacituzumab TirumotecanPhase 1/2Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
Est. primary completion 2028-05-09 · NCT06445972 · CT.gov ↗
What to watch
June 2028 (1)
Sacituzumab TirumotecanPhase 3Cervical Cancer
Est. primary completion 2028-06-15 · NCT06459180 · CT.gov ↗
What to watch
August 2028 (2)
Est. primary completion 2028-08 · NCT07697586 · CT.gov ↗
What to watch
Sacituzumab TirumotecanPhase 3Non-small Cell Lung Cancer (NSCLC)
Est. primary completion 2028-08-17 · NCT06305754 · CT.gov ↗
What to watch
September 2028 (1)
SKB571Phase 2HNSCC
Est. primary completion 2028-09-30 · NCT07668154 · CT.gov ↗
What to watch
October 2028 (1)
WIN378Phase 2Asthma
Est. primary completion 2028-10-01 · NCT07120503 · CT.gov ↗
What to watch
December 2028 (2)
SKB571Phase 2Non-Small Cell Lung Cancer
Est. primary completion 2028-12-31 · NCT07622186 · CT.gov ↗
What to watch
TagitanlimabPhase 2Small Cell Lung Cancer
Est. primary completion 2028-12-31 · NCT07296809 · CT.gov ↗
What to watch
2029 (10)
January 2029 (1)
Sacituzumab TirumotecanPhase 3Non-small Cell Lung Cancer, NSCLC
Est. primary completion 2029-01-12 · NCT06422143 · CT.gov ↗
What to watch
February 2029 (1)
CR-001Phase 1/2Locally Advanced / Metastatic Solid Tumors
Est. primary completion 2029-02 · NCT07335497 · CT.gov ↗
What to watch
April 2029 (2)
SKB571Phase 1/2Advanced Solid Tumors, Malignant Neoplasm
Est. primary completion 2029-04-12 · NCT07876128 · CT.gov ↗
What to watch
Sacituzumab TirumotecanPhase 3Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Est. primary completion 2029-04-27 · NCT06824467 · CT.gov ↗
What to watch
July 2029 (1)
Sacituzumab TirumotecanPhase 3Bladder Cancer
Est. primary completion 2029-07-27 · NCT07419295 · CT.gov ↗
What to watch
August 2029 (1)
Sacituzumab TirumotecanPhase 1/2Lung Neoplasm Malignant
Est. primary completion 2029-08-17 · NCT07286149 · CT.gov ↗
What to watch
September 2029 (1)
Sacituzumab TirumotecanPhase 1/2Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
Est. primary completion 2029-09-12 · NCT06469944 · CT.gov ↗
What to watch
October 2029 (1)
Sacituzumab TirumotecanPhase 1/2Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
Est. primary completion 2029-10-16 · NCT06428409 · CT.gov ↗
What to watch
November 2029 (1)
Sacituzumab TirumotecanPhase 2Malignant Neoplasm
Est. primary completion 2029-11-15 · NCT07252739 · CT.gov ↗
What to watch
December 2029 (1)
Sacituzumab TirumotecanPhase 1/2Advanced Solid Tumors
Est. primary completion 2029-12 · NCT07586943 · CT.gov ↗
What to watch
2030 (2)
May 2030 (1)
Sacituzumab TirumotecanPhase 3Triple Negative Breast Neoplasms
Est. primary completion 2030-05-18 · NCT06841354 · CT.gov ↗
What to watch
December 2030 (1)
Sacituzumab TirumotecanPhase 3Triple-Negative Breast Cancer
Est. primary completion 2030-12-16 · NCT06393374 · CT.gov ↗
What to watch
2031 (3)
September 2031 (1)
Sacituzumab TirumotecanPhase 2Advanced Solid Tumors, Malignant Neoplasm
Est. primary completion 2031-09-30 · NCT07785609 · CT.gov ↗
What to watch
October 2031 (1)
Sacituzumab TirumotecanPhase 3Cervical Cancer
Est. primary completion 2031-10-29 · NCT07216703 · CT.gov ↗
What to watch
November 2031 (1)
Sacituzumab TirumotecanPhase 3Bladder Cancer
Est. primary completion 2031-11-17 · NCT07829783 · CT.gov ↗
What to watch
2032 (4)
January 2032 (1)
Sacituzumab TirumotecanPhase 1/2Esophageal Squamous Cell Carcinoma
Est. primary completion 2032-01-04 · NCT06780111 · CT.gov ↗
What to watch
February 2032 (1)
Sacituzumab TirumotecanPhase 2Lung Neoplasm Malignant
Est. primary completion 2032-02-06 · NCT06788912 · CT.gov ↗
What to watch
May 2032 (1)
Sacituzumab TirumotecanPhase 3Endometrial Cancer
Est. primary completion 2032-05-24 · NCT06952504 · CT.gov ↗
What to watch
June 2032 (1)
Sacituzumab TirumotecanPhase 1/2Metastatic Castration-resistant Prostate Cancer
Est. primary completion 2032-06-29 · NCT07908524 · CT.gov ↗
What to watch
2033 (2)
February 2033 (1)
Sacituzumab TirumotecanPhase 3Ovarian Neoplasms, Ovarian Cancer
Est. primary completion 2033-02-25 · NCT07318558 · CT.gov ↗
What to watch
March 2033 (1)
Sacituzumab TirumotecanPhase 3Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
Est. primary completion 2033-03-23 · NCT06966700 · CT.gov ↗
What to watch
2034 (1)
February 2034 (1)
Sacituzumab TirumotecanPhase 3Non Small Cell Lung Cancer
Est. primary completion 2034-02-21 · NCT06312137 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 September 2026Topline resultWIN378 (HBM9378)Positive interim results from the Phase 2 portion of POLARIS-1 (WIN378/HBM9378, asthma); Phase 3 portion started
Windward Bio · Source ↗
30 July 2026Filing acceptedSacituzumab tirumotecan (sac-TMT)NMPA accepts the new indication application for sac-TMT in first-line advanced TNBC
China, NMPA · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Source ↗

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-H1$131M$84M$632M$20Mreport ↗

For the first half of 2025, Sichuan Kelun-Biotech reported revenue of $131.14M, R&D spend of $84.38M, and cash and equivalents of $632.1M. Net income/loss was not disclosed; the company recorded a quarterly net burn of $20.04M.

The company is commercializing sac-TMT, tagitanlimab, and cetuximab N01, with total commercial sales of RMB309.8 million in the period, and expects to launch trastuzumab botidotin and file an NDA for A400 in the second half of 2025. Sac-TMT received NMPA marketing authorization for EGFR-mutant NSCLC in March 2025 and an NDA acceptance with priority review for HR+/HER2- breast cancer in May 2025, while partner MSD is running 14 ongoing global Phase 3 studies of the asset. Trastuzumab botidotin's NDA for HER2+ breast cancer was accepted in January 2025. The company is also advancing earlier-stage candidates including SKB410/MK-3120, SKB571/MK-2750, and SKB378/WIN378, alongside collaborations with Ellipses Pharma and Windward Bio.

Annual history (2 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$287M$184M$651M$53Mreport ↗
View 1 more year
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$269M—$421M$37Mreport ↗